CommercialMay 1, 2021
Specialty pharmacy prior authorization update - certain drugs for treatment of ocular conditions continue to require prior authorization
In the March 2021 issue of Provider News, we advised we would no longer require prior authorization for the following drugs used to treat ocular conditions effective May 1, 2021. Please be advised that prior authorization will continue to be required for these drugs. We apologize for any inconvenience.
Drug |
Code |
Code description |
*Avastin |
C9257 J9035 |
intravitreal bevacizumab |
*Mvasi |
Q5107 |
bevacizumab-awwb |
*Zirabev |
Q5118 |
bevacizumab-bvzr |
*Non-oncology use is managed by Anthem’s medical specialty drug review team.
PUBLICATIONS: May 2021 Anthem Connecticut Provider News
To view this article online:
Or scan this QR code with your phone